Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
June 06, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Host KOL Event on June 16, 2022

LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces it will host an in-person KOL event for analysts and investors on...
May 25, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Present at Jefferies Healthcare Conference

LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a...
May 09, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022

LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
May 04, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma Announces May 2022 Investor Conference Participation

LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022: ...
May 03, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022 James Brady joined the Board as Non-Executive Director Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and...
April 19, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
March 14, 2022 03:00 ET | Source: Verona Pharma plc

James Brady Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
March 03, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Phase 3 ENHANCE program on track to report top-line COPD data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- Verona...
February 17, 2022 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...